Blog

Rockfire Resources PLC (LSE:ROCK) has released its unaudited interim results for the first half of 2025, showing a smaller loss compared to the same period last year. The company continues to advance its flagship Molaoi project in Greece, with plans to upgrade the resource category from Inferred to Indicated and begin pre-feasibility studies.

To strengthen technical oversight, Rockfire has appointed Steven Hunt to its Board. In parallel, the company’s collaboration with Sunshine Metals on the Lighthouse deposit in Australia is moving forward, with recent drilling highlighting encouraging gold and silver results that could accelerate resource development.

About Rockfire Resources

Rockfire Resources PLC is a mineral exploration company focused on zinc, germanium, silver, lead, gold, and copper. Its core project is the Molaoi zinc/germanium/silver/lead deposit in Greece, while in Australia it is progressing the Lighthouse Au-Ag deposit in Queensland.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Creo Medical (LSE:CREO) has reported notable progress across both its clinical programs and operational performance. The company has begun clinical studies for its MicroBlate Flex device, marking a key step forward in expanding its cancer treatment portfolio. At the same time, operational efficiency has improved, with costs reduced by 24%.

A strategic transaction — the sale of a 51% stake in CME to Micro-Tech — has further strengthened Creo’s commercial platform and balance sheet. While overall sales declined, revenue from continuing operations rose by 40%, reflecting greater clinical adoption of its devices. Management maintains a positive outlook, citing expectations of sustained revenue growth and future cashflow self-sufficiency.

Despite these advances, the company’s broader financial picture remains challenging, with declining overall revenues and continued losses weighing on results. Technical analysis points to a mixed outlook, showing some near-term positive momentum, but the valuation remains constrained by negative earnings. With no recent earnings calls or corporate updates, external events currently have little influence on sentiment.

About Creo Medical

Creo Medical is a medical technology company specializing in advanced energy-based devices for cancer treatment. Its MicroBlate technology is designed for tumor ablation across multiple cancers, including lung, pancreatic, liver, kidney, and bladder. The company is focused on accelerating clinical adoption of its innovations while expanding access to next-generation oncology solutions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Manx Financial Group PLC (LSE:MFX) has reported interim results showing a 16% rise in profit before tax to £4.1 million for the first half of 2025, even as broader economic conditions remain challenging. The group achieved record profitability alongside strong loan book growth, supported by its strategic priorities of expansion, operational simplification, and technology upgrades.

The company’s balance sheet reflected both higher lending volumes and stronger liquidity. At the same time, initiatives to broaden product offerings and improve investor engagement continue to move forward. Looking ahead, the group plans a cautious entry into EU markets while seeking to capture opportunities in short-term lending.

From a market perspective, Manx Financial’s stock performance remains strong, underpinned by healthy financials, disciplined expansion, and appealing valuation metrics. While technical indicators point to bullish momentum, analysts note the potential for overbought conditions.

About Manx Financial Group

Manx Financial Group PLC is a diversified financial services group that includes Conister Bank Limited, Conister Finance & Leasing Ltd, MFX Limited, Payment Assist Limited, and other subsidiaries. Operating primarily in the Isle of Man and the UK, the group offers services spanning banking, finance, leasing, and wealth management.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

N4 Pharma (LSE:N4P) has announced a breakthrough in its collaboration with SRI, successfully demonstrating targeted RNA delivery to non-small cell lung cancer cells through its Nuvec® technology. This achievement highlights the platform’s potential as a distinct delivery system for RNA-based therapies, particularly in oncology. It also strengthens N4 Pharma’s position in the growing RNA therapeutics market and increases opportunities for future strategic collaborations.

About N4 Pharma

N4 Pharma plc is a UK biotechnology company developing Nuvec®, its proprietary gene delivery platform. Designed to support advanced therapies for cancer and other diseases, Nuvec® addresses critical challenges in the RNA therapeutics space by offering more precise and efficient delivery methods. With the RNA therapeutics market expected to expand significantly, N4 Pharma aims to capitalize on demand for innovative, targeted treatment solutions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Argo Blockchain (LSE:ARB) has appointed Charlotte Proctor-Worrall as its new Chief Financial Officer. The promotion highlights her key role in strengthening the company’s financial framework and supporting major strategic transactions.

In a parallel development, Argo secured approval from Nasdaq to maintain its listing, provided it achieves compliance requirements by January 2026. The extension is tied to the company’s ongoing recapitalization initiative with Growler Mining.

About Argo Blockchain

Argo Blockchain plc is a blockchain technology company dually listed in London and New York, with a focus on large-scale cryptocurrency mining. The company operates a facility in Quebec and maintains offices across the US, Canada, and the UK. Known for its sustainability efforts, Argo powers its operations primarily with renewable energy and was the first cryptocurrency miner to achieve climate-positive status after joining the Crypto Climate Accord.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Kavango Resources (LSE:KAV) has reported positive results from its drilling program at the Bill’s Luck Gold Mine in Zimbabwe. The company confirmed significant gold intersections from the first two completed diamond drill holes, marking an important milestone in its strategy to move from exploration toward large-scale production. These results form the basis for establishing an initial mineral resource estimate, a key step in advancing the project.

Looking ahead, Kavango plans to continue shaft sinking to expand mining operations and increase output, with the goal of strengthening its market presence and delivering meaningful returns to stakeholders.

About Kavango Resources

Kavango Resources PLC is a metals exploration and development company focused on Southern Africa. In Zimbabwe, the group is advancing a portfolio of gold projects, including the Hillside and Nara properties, which it owns outright. Its strategy centers on transforming high-potential exploration sites into commercially viable mining operations using modern, mechanized methods across both open-pit and underground settings.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Rainbow Rare Earths (LSE:RBW) has announced major progress at its Phalaborwa project following the successful application of a cerium depletion process. This development improves the grade of its mixed rare earth product while lowering production costs, strengthening Phalaborwa’s position as a competitive, low-cost supplier of critical rare earths. The advancement supports the company’s ambition to become a key contributor to the green technology supply chain and is expected to positively influence both market positioning and stakeholder confidence.

The company’s near-term outlook, however, is still shaped by its financial challenges. With no revenue generation to date and continuing losses, Rainbow faces considerable risks. Even so, technical signals point to bullish momentum, bolstered by the progress of strategic initiatives like Phalaborwa. While its valuation remains difficult due to negative earnings, the company’s growth pipeline and project milestones provide a degree of optimism for investors.

About Rainbow Rare Earths

Rainbow Rare Earths is working to build an independent and sustainable supply chain for rare earth elements that are vital to the clean energy transition. Its innovative process focuses on extracting these materials from phosphogypsum, a by-product of phosphoric acid production, enabling faster and more cost-effective output than conventional mining methods. The company’s flagship projects include Phalaborwa in South Africa and Uberaba in Brazil, with a focus on rare earths used in high-performance permanent magnets such as neodymium, praseodymium, dysprosium, and terbium.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Ondo InsurTech Plc (LSE:ONDO) has reported notable progress in its business development, particularly across the U.S. market. The company recently unveiled a new collaboration with Bear River Mutual while also deepening existing insurer partnerships, resulting in a sharp increase in LeakBot device shipments. In the UK, Ondo has renewed its long-standing agreement with Admiral, while in Denmark it has extended its presence through If P&C Insurance. Customer satisfaction levels remain strong, and fresh appointments to the board are expected to boost governance and strategic capabilities. Looking ahead, Ondo is focused on scaling its LeakBot technology worldwide, with an emphasis on building stronger ties with leading insurers in the U.S. to fuel growth and strengthen its competitive position.

The company’s outlook continues to be shaped by a mix of strong revenue momentum and ongoing financial headwinds. While sales growth has been robust, profitability and balance sheet stability remain challenging areas. Technical indicators suggest some positive momentum, but valuation remains under pressure due to a negative price-to-earnings ratio and the absence of dividend payments. With no recent earnings calls or corporate announcements, these factors currently have little impact on the near-term outlook.

About Ondo InsurTech Plc

Ondo InsurTech Plc specializes in claims prevention technology for the home insurance sector. Its LeakBot system is designed to help insurers and homeowners minimize water damage claims. The company maintains a growing footprint across both the U.S. and European markets.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

U.S. stock futures point to a modestly higher open on Friday, suggesting that equities could extend the gains seen in the previous session.

Markets have been buoyed by recent momentum, which has lifted the major indexes to new record highs. Despite September historically being one of the weaker months for stocks, the benchmarks have moved higher over the first weeks of the month.

Investor optimism has been fueled by lower interest rates, following the Federal Reserve’s 25-basis-point cut on Wednesday and its indication of two additional rate reductions later this year.

Traders will also be watching a scheduled phone conversation between President Donald Trump and Chinese President Xi Jinping, which could finalize an agreement on TikTok’s U.S. operations.

Trading activity may remain somewhat muted, as the absence of major U.S. economic reports could keep some participants on the sidelines. Uncertainty over the next significant market catalyst after the Fed’s rate cut may also weigh on volume.

On Thursday, equities extended their early gains throughout the day, building on a mixed session on Wednesday to reach new record closing highs. The Nasdaq led the advance, climbing 209.40 points, or 0.9%, to 22,470.73. The S&P 500 rose 31.61 points, or 0.5%, to 6,631.96, while the Dow added 124.10 points, or 0.3%, to 46,142.42.

Tech stocks played a key role in driving the rally, particularly Intel (NASDAQ:INTC), which surged 22.8% to its highest closing level in over a year. The jump followed Intel’s announcement of a partnership with Nvidia (NASDAQ:NVDA) to co-develop several generations of custom data center and PC products. Nvidia, which had seen losses in recent sessions, rose 3.5% and will invest $5 billion in Intel’s common stock at $23.28 per share.

CrowdStrike (NASDAQ:CRWD) also gained 12.8% after providing strong guidance and unveiling a strategic partnership with Salesforce (NYSE:CRM) during an investor day on Wednesday.

On the economic front, the Labor Department reported that initial jobless claims fell by more than expected to 231,000 for the week ending September 13, a decrease of 33,000 from the previous week’s revised total of 264,000. Economists had anticipated claims would drop to 240,000 from 263,000.

Separately, the Conference Board’s leading economic index fell 0.5% in August, following a revised 0.1% rise in July, a sharper decline than the 0.1% drop economists had expected.

Semiconductor stocks rallied alongside Intel, lifting the Philadelphia Semiconductor Index by 3.6% to a record closing high. Other technology sectors, including computer hardware and biotechnology, also showed notable strength, contributing to the Nasdaq’s advance.

Financials performed strongly as well, with the KBW Bank Index up 1.4% and the NYSE Arca Broker/Dealer Index rising 1.3%.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

European equities are showing muted activity on Friday as the week wraps up after a series of key central bank decisions.

Economic data from the U.K. provided some support, with retail sales rising for the third consecutive month in August. The Office for National Statistics reported that retail sales volumes climbed 0.5% compared with July, slightly above economists’ expectation of a 0.4% increase. July’s figures were also revised upward to a 0.5% gain.

In market movements, Germany’s DAX Index slipped 0.1%, while the U.K.’s FTSE 100 hovered near flat and France’s CAC 40 inched 0.2% higher.

Corporate activity drove notable stock moves. British telecom giant Vodafone (LSE:VOD) surged after announcing its acquisition of Telekom Romania Mobile Communications S.A., including its post-paid subscriber base, for €30 million.

IG Group Holdings (LSE:IGG) declined following news of its takeover of Independent Reserve, a prominent Australian cryptocurrency exchange.

Meanwhile, Close Brothers (LSE:CBG) fell after delaying the release of its preliminary 2025 results by a week. Auto parts supplier Stabilus (TG:STM) also retreated after lowering its net profit forecast below market expectations.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.